GlassScriptPhysician profile
Lowell L Hart
NPI 1245221993
$256,520.87
in general payments reported to CMS, 2019-2025
100 companies · $8,048 in 2025
The $8,048 reported for 2025 was more than what 79% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $159K · 2020: $51K · 2021: $8,963 · 2022: $6,213 · 2023: $9,319 · 2024: $13K · 2025: $8,048.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Consulting Fee: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,270 · Travel and Lodging: $867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,937.20 |
| Consulting Fee | $10,717.07 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,270.13 |
| Travel and Lodging | $867.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $73,121.70 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Novartis Pharmaceuticals Corporation | $54,197.78 | 2019-2025 | Kisqali, Piqray |
| Genentech USA, INC. | $23,472.77 | 2019-2024 | Tecentriq, Alecensa, Gavreto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15,327.74 | 2019-2025 | Gilotrif |
| F. Hoffmann-La Roche Ag | $15,170.17 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13,887.27 | 2019-2025 | Enhertu, Imfinzi, Calquence |
| Seagen INC. | $10,549.30 | 2019-2023 | Adcetris, Tukysa, Padcev |
| Merck Sharp & Dohme LLC | $7,827.21 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Veracyte, INC. | $5,850.97 | 2020-2022 | |
| Daiichi Sankyo INC. | $4,685.74 | 2019-2025 | Enhertu, Injectafer |
| Janssen Biotech, INC. | $2,730.00 | 2020-2025 | Rybrevant, Darzalex, Tecvayli |
| Pfizer INC. | $2,576.11 | 2019-2025 | |
| Tesaro, INC. | $2,390.05 | 2019 | |
| Karyopharm Therapeutics INC. | $2,287.09 | 2020 | |
| Jazz Pharmaceuticals INC. | $1,967.81 | 2019-2025 |
Show all 94 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $1,742.59 | 2020 | |
| Celgene Corporation | $1,538.36 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Epizyme, INC. | $1,532.42 | 2021-2024 | Tazverik, Onivyde |
| E.R. Squibb & Sons, L.L.C. | $1,501.89 | 2019-2025 | Opdivo, Onureg, Opdualag |
| Boehringer Ingelheim International Gmbh | $1,057.63 | 2023 | |
| Incyte Corporation | $837.18 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Genzyme Corporation | $774.95 | 2019-2025 | |
| Exelixis INC. | $757.20 | 2019-2025 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $720.90 | 2019-2025 | |
| Gilead Sciences, INC. | $705.77 | 2021-2025 | Trodelvy |
| Amgen INC. | $684.89 | 2019-2023 | Lumakras |
| Eisai INC. | $583.31 | 2019-2025 | |
| Beigene USA, INC. | $562.68 | 2020-2025 | Brukinsa, Tevimbra |
| Athenex Pharmaceutical Division, LLC | $500.00 | 2020 | |
| Foundation Medicine, INC. | $415.04 | 2019-2020 | |
| Astellas Pharma US INC | $369.30 | 2019-2025 | Vyloy, Padcev, Xtandi |
| Takeda Pharmaceuticals U.S.A., INC. | $352.08 | 2019-2025 | Ninlaro, Fruzaqla, Hyqvia |
| Glaxosmithkline, LLC. | $339.52 | 2020-2025 | Ojjaara, Zejula, Shingrix |
| Puma Biotechnology, INC. | $316.87 | 2019-2025 | |
| G1 Therapeutics, INC. | $290.41 | 2021-2022 | |
| Abbvie INC. | $277.91 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $273.34 | 2019-2025 | Libtayo |
| Array Biopharma INC | $263.36 | 2020-2025 | Braftovi, Mektovi, Lorbrena |
| Mirati Therapeutics, INC. | $214.38 | 2023-2024 | Krazati |
| Ipsen Biopharmaceuticals, INC | $211.63 | 2019-2025 | Onivyde |
| Pharmacosmos Therapeutics INC. | $195.64 | 2024-2025 | Cosela, Monoferric |
| Pharmacyclics LLC, An Abbvie Company | $174.64 | 2019-2023 | Imbruvica |
| Emd Serono, INC. | $165.02 | 2019-2025 | Bavencio |
| Sobi, INC | $158.65 | 2022-2025 | |
| Cti Biopharma Corp. | $158.28 | 2022-2023 | Vonjo |
| Spectrum Pharmaceuticals INC. | $158.27 | 2023 | Rolvedon |
| Adaptive Biotechnologies Corporation | $156.43 | 2022-2025 | Clonoseq |
| Tersera Therapeutics LLC | $150.18 | 2019-2024 | Zoladex |
| Verastem, INC. | $137.80 | 2019 | |
| Dendreon Pharmaceuticals LLC | $135.99 | 2025 | Provenge |
| Nanostring Technologies, INC. | $135.02 | 2019 | |
| Legend Biotech USA INC. | $134.75 | 2024-2025 | Carvykti |
| Dova Pharmaceuticals | $134.52 | 2020-2021 | |
| Clovis Oncology, INC. | $110.18 | 2019-2021 | |
| Tempus Ai, INC | $99.29 | 2025 | Xt Cdx |
| Pharmaessentia USA Corporation | $92.26 | 2022-2023 | Besremi |
| Kyowa Kirin, INC. | $80.70 | 2022-2024 | Poteligeo |
| Beone Medicines USA, INC. | $76.36 | 2025 | Brukinsa, Tevimbra |
| Sumitomo Pharma America, INC. | $74.78 | 2023-2025 | Orgovyx |
| Stemline Therapeutics INC. | $73.37 | 2023-2025 | Orserdu |
| Servier Pharmaceuticals LLC | $66.82 | 2023-2025 | |
| Kite Pharma, INC. | $66.61 | 2021-2023 | Yescarta |
| Alnylam Pharmaceuticals INC. | $60.32 | 2022-2023 | Onpattro |
| Myriad Genetic Laboratories, INC. | $53.06 | 2023-2024 | Precisetumor, Myrisk |
| Springworks Therapeutics, INC. | $51.50 | 2024-2025 | Ogsiveo |
| Geron Corporation | $49.11 | 2025 | Rytelo |
| Alexion Pharmaceuticals, INC. | $48.85 | 2023-2025 | Ultomiris |
| Eusa Pharma (US) LLC | $48.44 | 2019 | |
| Sirtex Medical INC | $45.99 | 2020-2024 | Sir-Spheres Microspheres |
| Myovant Sciences INC. | $42.67 | 2022 | |
| Genmab U.S., INC. | $41.93 | 2024 | Epkinly |
| Menarini Silicon Biosystems, INC. | $37.54 | 2023 | Cellsearch |
| Adc Therapeutics America, INC. | $37.47 | 2023-2024 | |
| Rigel Pharmaceuticals, INC. | $32.52 | 2024 | Rezlidhia, Tavalisse |
| Morphosys, US INC. | $32.05 | 2023 | Monjuvi |
| Ge Healthcare | $30.34 | 2021 | |
| Aurobindo Pharma USA, INC. | $28.48 | 2019 | |
| Amag Pharmaceuticals, INC. | $26.98 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $21.32 | 2025 | |
| Syndax Pharmaceuticals, INC. | $21.10 | 2025 | |
| Agios Pharmaceuticals, INC. | $18.57 | 2025 | Pyrukynd |
| Advanced Accelerator Applications | $18.38 | 2019 | |
| Immunogen, INC. | $17.99 | 2023 | Elahere |
| Taiho Oncology, INC. | $17.71 | 2025 | |
| Helsinn Therapeutics (U.S.), INC. | $17.13 | 2019 | |
| Heron Therapeutics, INC. | $16.85 | 2022 | |
| Aveo Pharmaceuticals, INC. | $16.65 | 2023 | Fotivda |
| Acrotech Biopharma INC. | $15.55 | 2023 | Beleodaq |
| Azurity Pharmaceuticals, INC. | $14.12 | 2025 | Danziten |
| Deciphera Pharmaceuticals INC. | $13.59 | 2022 | |
| Secura Bio, INC. | $13.42 | 2020 | |
| Global Blood Therapeutics, INC. | $12.99 | 2021 | |
| Iovance Biotherapeutics, INC. | $8.98 | 2024 | Amtagvi |
| Janssen Scientific Affairs, LLC | $8.39 | 2024 | Rybrevant |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$21,259.17 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lowell Hart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.